摘要
目的:探讨髓过氧化物酶(MPO)预警健康及亚健康人群发生急性冠状动脉综合征(ACS)的应用价值。方法:回顾性分析2021年5月—2023年5月于赣州市人民医院进行体检的90例体检者资料,将健康人群作为对照组,亚健康人群为研究组,各45例。测量并分析两组的MPO、肌酸激酶同工酶和肌酸激酶水平,使用ROC曲线分析MPO、肌酸激酶同工酶和肌酸激酶水平对亚健康人群发生ACS的预测价值。结果:研究组的MPO、肌酸激酶同工酶、肌酸激酶水平均高于对照组,差异均有统计学意义(P<0.05)。ROC曲线分析,MPO水平的曲线下面积为0.92、灵敏度为0.93、特异度为0.88,其预测价值高于肌酸激酶同工酶和肌酸激酶水平。结论:相比较健康人群,亚健康人群的MPO水平会异常升高,对亚健康人群发生ACS具有重要的预测价值。通过检测MPO水平,可以发现亚健康人群潜在的心血管问题,为早期预防和治疗提供诊断依据,降低ACS的发生风险。
Objective:To investigate the application value of myeloperoxidase(MPO)in early warning of acute coronary syndrome(ACS)in healthy and sub-healthy people.Methods:The data of 90 individuals who underwent physical examination in Ganzhou People's Hospital from May 2021 to May 2023 were retrospectively analyzed.Healthy individuals serving as the control group and sub-health individuals as the research group,each with 45 cases.The levels of MPO,Creatine Kinas isoenzyme and Creatine Kinase in the two groups were measured and analyzed.ROC curve was used to analyze the predictive value of MPO,CK isoenzyme and creatine kinase levels in the occurrence of ACS in sub-healthy people.Results:The levels of MPO,Creatine Kinas isoenzyme and Creatine Kinase in study group were higher than those in control group,and the differences were statistically significant(P<0.05).ROC curve analysis showed that the area under curve,sensitivity and specificity of MPO level were 0.92,0.93 and 0.88,which were higher than Creatine Kinas isoenzyme and Creatine Kinase levels.Conclusion:Compared with the healthy population,the MPO level of sub-healthy population will increase abnormally,which has important predictive value for the occurrence of ACS in sub-healthy population.By detecting MPO levels,potential cardiovascular problems in sub-healthy people can be found,providing diagnostic basis for early prevention and treatment,and reducing the risk of ACS.
作者
林燕
LIN Yan(Department of Laboratory,Ganzhou People’s Hospital,Ganzhou 341000,China)
出处
《中国伤残医学》
2024年第16期115-118,共4页
Chinese Journal of Trauma and Disability Medicine
基金
赣州市指导性科技计划(GZ2020ZSF186)。